Grace Taylor, MS, MA

News
A Deep Learning Model for Predicting Immune Checkpoint Inhibitor Efficacy in NSCLC
01/08/2025
Researchers developed and validated a deep learning model, Deep-IO, designed to predict the efficacy of immune checkpoint inhibitors (ICIs) in treating advanced non-small cell lung cancer (NSCLC), according to a study published in JAMA...
Researchers developed and validated a deep learning model, Deep-IO, designed to predict the efficacy of immune checkpoint inhibitors (ICIs) in treating advanced non-small cell lung cancer (NSCLC), according to a study published in JAMA...
Researchers developed and...
01/08/2025
Journal of Clinical Pathways
News
COVID-19 Infection Linked to Increased Risk of Skin Conditions
01/08/2025
A recent study found that COVID-19 infection significantly increases the risk of developing skin conditions such as vitiligo, chronic urticaria, alopecia areata, and herpes zoster.
A recent study found that COVID-19 infection significantly increases the risk of developing skin conditions such as vitiligo, chronic urticaria, alopecia areata, and herpes zoster.
A recent study found that...
01/08/2025
First Report Managed Care
Conference Coverage
Impact of Clinical Pharmacist-Led Non-Oncology Infusion Management
12/11/2024
A study presented at the 2024 ASHP Midyear Clinical Meeting evaluated the impact of a pharmacist-led non-oncology infusion therapy management protocol, showing improvements in operational efficiency and other areas.
A study presented at the 2024 ASHP Midyear Clinical Meeting evaluated the impact of a pharmacist-led non-oncology infusion therapy management protocol, showing improvements in operational efficiency and other areas.
A study presented at the 2024...
12/11/2024
Pharmacy Learning Network
Conference Coverage
Impact of Prior Authorization Removal on SGLT2 Inhibitor Utilization
12/10/2024
At the 2024 ASHP Midyear Clinical Meeting, researchers presented on the impact of removing prior authorization (PA) restrictions on the utilization of sodium-glucose co-transporter-2 inhibitors (SGLT2i) in a primary care safety net clinic...
At the 2024 ASHP Midyear Clinical Meeting, researchers presented on the impact of removing prior authorization (PA) restrictions on the utilization of sodium-glucose co-transporter-2 inhibitors (SGLT2i) in a primary care safety net clinic...
At the 2024 ASHP Midyear...
12/10/2024
Pharmacy Learning Network
News
The Ongoing Impact of COVID-19 on Caregivers of Patients With Chronic Lymphocytic Leukemia
03/15/2023
A recent study investigated the impact of COVID-19 on caregivers of patients with CLL during the post-vaccine phase of the pandemic and aimed to identify what resources are needed to better support these caregivers.
A recent study investigated the impact of COVID-19 on caregivers of patients with CLL during the post-vaccine phase of the pandemic and aimed to identify what resources are needed to better support these caregivers.
A recent study investigated the...
03/15/2023
Journal of Clinical Pathways
Conference Coverage
Treating Advanced Melanoma With Fianlimab and Cemiplimab
06/01/2023
Researchers at ASCO 2023 presented data on the outcomes of treating patients with advanced melanoma, including patients who previously received adjuvant therapy, with fianlimab and cemiplimab.
Researchers at ASCO 2023 presented data on the outcomes of treating patients with advanced melanoma, including patients who previously received adjuvant therapy, with fianlimab and cemiplimab.
Researchers at ASCO 2023...
06/01/2023
First Report Managed Care
News
NCCN Updates Clinical Practice Guidelines for B-Cell Lymphomas
10/17/2023
NCCN recently published updated recommendations for the treatment of diffuse large B-cell lymphoma (DLBCL) and histologic transformation of indolent lymphomas to DLBCL.
NCCN recently published updated recommendations for the treatment of diffuse large B-cell lymphoma (DLBCL) and histologic transformation of indolent lymphomas to DLBCL.
NCCN recently published updated...
10/17/2023
Pharmacy Learning Network
News
Analysis of Racial Disparities in Cancer-Specific Survival Rates of Patients with Diffuse Large B-Cell Lymphoma
07/06/2023
In a recent study, Soyon Lee, MPH, and John D. Seeger, PhD, Harvard T.H. Chan School of Public Health, Boston, MA, examined the association between race and cancer-specific survival among patients with diffuse large B-cell lymphoma.
In a recent study, Soyon Lee, MPH, and John D. Seeger, PhD, Harvard T.H. Chan School of Public Health, Boston, MA, examined the association between race and cancer-specific survival among patients with diffuse large B-cell lymphoma.
In a recent study, Soyon Lee,...
07/06/2023
Journal of Clinical Pathways
News
FDA Approves Belzutifan for Patients With Advanced Renal Cell Carcinoma
01/23/2024
The FDA has granted approval to belzutifan for patients with advanced renal cell carcinoma after they have received a PD-1 or PD-L1 inhibitor and a VEGF-TKI.
The FDA has granted approval to belzutifan for patients with advanced renal cell carcinoma after they have received a PD-1 or PD-L1 inhibitor and a VEGF-TKI.
The FDA has granted approval to...
01/23/2024
Journal of Clinical Pathways
Lenvatinib and Pembrolizumab Combination Therapy for the Treatment of Endometrial Cancer: A Real-World Study
11/07/2023
Keiko Wada, MS, IQVIA Inc, and colleagues analyzed the treatment and dosing patterns of lenvatinib and pembrolizumab combination therapy for patients with endometrial cancer in the US.
Keiko Wada, MS, IQVIA Inc, and colleagues analyzed the treatment and dosing patterns of lenvatinib and pembrolizumab combination therapy for patients with endometrial cancer in the US.
Keiko Wada, MS, IQVIA Inc, and...
11/07/2023
Journal of Clinical Pathways

Upcoming Events

February 2 ⁠–⁠ February 5
LLM Winter Symposium
February 7 ⁠–⁠ February 9
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
GD Solid Tumors
March 22 ⁠–⁠ March 23
NP Institute
March 27 ⁠–⁠ March 30
TCIV
March 31 ⁠–⁠ April 2
Rx summit logo
April 21 ⁠–⁠ April 24
Symposium on Advanced Wound Care
April 30 ⁠–⁠ May 4
WoundCon
May 1 ⁠–⁠ May 3
See Full Calendar

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use